WIPO logo
Mobile | Deutsch | English | Español | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Recherche dans les collections de brevets nationales et internationales
World Intellectual Property Organization
Recherche
 
Options de navigation
 
Traduction
 
Options
 
Quoi de neuf
 
Connexion
 
Aide
 
maximize
Traduction automatique
1. (WO2008126932) RÉGULATION ÉPIGÉNÉTIQUE DE LA PLASTICITÉ DU CERVEAU
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

CLAIMS

1. An agent for regulating brain plasticity, which comprises a substance affecting an epigenetic state selected from the group consisting of histone
acetylation and DNA methylation.

2. The agent according to claim 1, wherein the
substance induces histone hyperacetylation or DNA
demethylation.

3. The agent according to claim 2, wherein the
substance is a histone deacetylase inhibitor or a DNA methyltransferase inhibitor.

4. The agent according to claim 2, wherein the histone deacetylase inhibitor is selected from the group
consisting of a short chain fatty acid or a derivative thereof; a hydroxamic acid derivative; a Benzamide derivative; a cyclic tetrapeptide; an electrophilic ketone derivative; and a psammaplin or Depudecin.

5. The agent according to claim 4, wherein the histone deacetylase inhibitor is valproic acid or trichostatin A, or a salt thereof.

6. The agent according to any of claims 1-5, which is for treating or preventing one or more diseases or conditions selected from the group consisting of
amblyopia, autism spectrum disorders, fragile X syndrome, Rubinstein-Taybi syndrome, mental retardation, Rett's syndrome, schizophrenia, bipolar disorder, Alzheimer's disease, depression, stroke, spinal muscular atrophy, brain lesion and ischemia.

7. A method for regulating brain plasticity in a mammal, which comprises regulating an epigenetic state selected from the group consisting of histone
acetylation and DNA methylation in said mammal.

8. A method for regulating brain plasticity in a mammal, which comprises administrating an effective amount of the agent according to any one of claims 1-6 to the mammal .

9. A use of a substance affecting an epigenetic state selected from the group consisting of histone
acetylation and DNA methylation, for production of an agent for regulating brain plasticity.

10. A substance affecting an epigenetic state selected from the group consisting of histone acetylation and DNA methylation, for use as an agent for regulating brain plasticity.

11. A commercial package comprising the agent according to any one of claims 1-6 and a written matter which states that the agent can or should be used for
regulating brain plasticity.